The best strategies for haploidentical stem cell transplants are not known. We used a standard myeloablative pretransplant conditioning regimen (30 mg/kg VP-16, 120 mg/kg cyclophosphamide, and 12 Gy of TBI in six fractions), an increased peripheral stem cell dose of Ͼ10 ؋ Unmanipulated hemopoietic stem cell transplants (HSCT) from haploidentical family donors carry a high risk of severe graft-versus-host disease (GVHD). T cell depletion increases the risk of graft failure and of infectious complications due to slow immune reconstitution. Additional immune suppression is then used to promote engraftment.
/l neutrophils at a median 12 (10-21) days. Graft failure in two consecutive patients out of four on the original protocol led to a modification adding ATG pretransplant and OKT3 post transplant. Graft failure was observed in one out of six subsequent patients. Acute GVHD уgrade II was observed in three patients. Three of 10 patients are alive in CR at Ͼ24 and Ͼ3 (2) months after transplant. Seven patients died: four of transplant related complications and three of relapse. Increased stem cell dose (у10 ؋ 10 6 CD34 ؉ cells/kg) as obtained using currently available technology may not be sufficient to ensure stable engraftment in patients with high-risk leukemia using standard myeloablative conditioning regimens. Bone Marrow Transplantation (2000) 26, 1033-1036. Keywords: stem cell dose; CD34 ϩ cell dose; engraftment; haploidentical; mismatched related donor Unmanipulated hemopoietic stem cell transplants (HSCT) from haploidentical family donors carry a high risk of severe graft-versus-host disease (GVHD). T cell depletion increases the risk of graft failure and of infectious complications due to slow immune reconstitution. Additional immune suppression is then used to promote engraftment. Recently, data from animal experiments and in vitro studies 13, 14 and from human transplantation [1] [2] [3] [4] 6, [15] [16] [17] have addressed the impact of stem cell dose. Previously, the achievable stem cell dose was limited by the amount of bone marrow that could be harvested. This has changed in the current era of allogeneic peripheral blood stem cell transplantation. 18 It was hypothesized, that a higher stem cell dose, as achieved by mobilizing peripheral blood stem cells may promote engraftment, and immune reconstitution and maintain graft-versus-leukemia effects despite extensive T cell depletion. We planned to test this hypothesis by using a protocol of an increased peripheral stem cell dose, a standard myeloablative conditioning regimen, T cell depletion, and a short course of post-transplant cyclosporine to promote engraftment. We report our initial experience with this protocol.
Patients and methods

Methods
Peripheral stem cells were mobilized by daily subcutaneous injection of 10 g/kg of G-CSF. Donors underwent 15-25 l apheresis on days 5-8 of G-CSF mobilization. The goal was to collect Ͼ10 ϫ 10 6 CD34 ϩ cells/kg. Allowing for a 50% loss during T cell depletion, Ͼ20 ϫ 10 6 CD34 ϩ cells/kg were collected. If this goal could not be reached, a second mobilization was planned. 19 The apheresis product was T cell-depleted using CD34 ϩ positive selection followed by CD4/CD8 depletion steps (Isolex 300i; Baxter, Deerfield, IL, USA) to achieve Ͻ1 ϫ 10 5 CD3 ϩ cells/kg. The transplants were cryopreserved using 10% DMSO as cryoprotectant and stored in the vapor phase of a liquid nitrogen tank at Ϫ196°C. Pretransplant conditioning was our standard regimen of 30 mg/kg VP-16, 120 mg/kg cyclophosphamide and TBI, 12 Gy in six fractions or busulphan 16 mg/kg and cyclophosphamide 120 mg/kg for patients who had undergone prior irradiation. The transplants were thawed at the bedside and infused rapidly on day 0. Cyclosporine was used for post-transplant immune suppression, tapered rapidly after day 14. Engraftment was defined as reaching 0.5 ϫ 10 9 /l neutrophils stable over 3 days, after a period of aplasia. The modified Glucksberg criteria were used to score acute graft-versus-host disease (GVHD). Prophylaxis of infectious complications included cotrimoxazole, acyclovir, fluconazole and weekly CMV antigenemia CR ϭ complete remission; CT ϭ chemotherapy; HSCT ϭ hemopoietic stem cell transplantation; CNS ϭ central nervous system.
monitoring. The mismatched HLA-haplotype, analyzed by SSP-DNA typing, was used as a marker for monitoring post-transplant chimerism. The maximum tolerable rate of graft rejection was estimated to be at approximately 10% using this protocol. Following graft failure in two out of four consecutive patients ATG 90 mg/kg (Lymphoglobuline; Mérieux, Lyon, France) over 3 days was added to the pretransplant conditioning regimen followed by OKT3 5 mg daily for 14 days post transplant. 6 
Patients
Patient and disease characteristics are listed in Table 1 . Of the 10 patients treated, four had AML, two MDS RAEBt, one CML and three a T-ALL. All suffered from advanced disease. Two patients had failed prior autologous HSCT, one patient had failed prior allogeneic HSCT from an HLAidentical sibling. Seven patients were male, median age was 11 years range (3-33).
Results
Transplant-related characteristics and outcome details are shown in Tables 2 and 3 . Donors were parents (eight) or siblings (two). Donors were truly haploidentical with 3/6 HLA antigen mismatches with their recipients. The median number of CD34 ϩ cells was 12.9 (9.5-45.7) ϫ 10 6 cells/kg. The targeted stem cell dose of 10 ϫ 10 6 CD34 ϩ cells/kg was reached in all but one patient. Stem cell mobilization was repeated in three donors, for recipients of higher weight. The stem cell dose infused was correlated to the patient's body weight (P ϭ 0.03 by Spearman's rank correlation) with small children receiving higher doses. The median number of CD3 cells was 0.41 (0.09-1.89) ϫ 10 5
CD3
ϩ cells/kg. The goal of T cell depletion to Ͻ1 ϫ 10 5 CD3 cells/kg was not reached in three patients. All patients engrafted initially and median days to achieve 0.5 ϫ 10 9 /l neutrophils was 12.
10-21 Three of 10 patients had graft failure. After rejection in two of four consecutive patients treated with myeloablative conditioning alone without additional immunosuppression, the conditioning regimen was changed to include ATG pretransplant and OKT3 post transplant. Graft failure occurred in one of six subsequent patients treated with the more immunosuppressive regimen. This difference of two patients with graft failure out of four on the original protocol vs one of six on the modified protocol is not statistically significant by the Fisher's exact test (P ϭ 0.3). There was no difference in graft failure whether patients received TBI (two of seven) or BuCy (one of three) conditioning. Grade II-IV GVHD was observed in three patients, it was mild in two, but lethal in the third. Three patients are alive and well (Table 3 ), but two of them have been followed for less than 6 months. Seven patients died, three patients of leukemia relapse, four of transplantrelated complications.
Discussion
These data show that haploidentical HSCT in patients with advanced leukemia remains difficult, even in the current era of stem cell engineering. We designed our protocol to answer the question whether an increased peripheral stem cell dose, as achieved with currently available technology, will overcome host-versus-graft reactions, after a standard myeloablative conditioning regimen and extensive T cell depletion without using additional immunosuppressive drugs such as ATG. There is evidence from animal and human studies that high ('mega') stem cell doses may promote engraftment, and may maintain graft-versus-leukemia effects in spite of T cell depletion, when transplanted in HLA-disparate donor-recipient pairs. [1] [2] [3] [4] 6, [13] [14] [15] [16] [17] We failed to demonstrate an effect of stem cell dose on host-versus-graft reactivity. After observing graft failure in two out of four patients, we included additional immunosuppressive drugs and there was graft failure in one out of six subsequent patients. Whether this rather high graft failure rate (30%) may be lowered by modifying the conditioning regimen is open to discussion. The Perugia group has used unfractionated TBI 1 and there is some evidence that fractionated TBI may be less immunosuppressive. 20 BuCy conditioning, given to previously irradiated patients was not associated with appreciably more graft rejection (one of three) than Cy/VP-16/TBI (two of seven).
Otherwise, outcome data presented here do not differ from other published studies in haploidentical HSCT where relapse of the original disease, 1 infectious complications, 12 and to a lesser degree graft failure and GVHD 1 are the main causes of death.
There is a complex interrelationship between stem cell dose (CD34 ϩ cell dose), extent of T cell depletion, intensity of the pretransplant conditioning regimen, post-transplant immunosuppression and the degree of HLA disparity. These factors will influence the rate of engraftment, the Bone Marrow Transplantation grade of acute and chronic GVHD, and the magnitude of the graft-versus-leukemia effect.
Results of this study should be interpreted cautiously. There is no significant difference in the graft failure rate between patients transplanted with or without added immunosuppressives. The initial 50% graft failure rate could represent a chance finding. For the sake of testing the hypothesis of the impact of increased stem cell dose on engraftment it would have been desirable to continue with the original protocol. The participating physicians felt constrained to add additional immunosuppressives in the light of this 50% graft failure rate. Finally, our observation may be specific for the type of conditioning regimen and T cell depletion used, and should therefore not be generalized to other situations.
The data presented here do not argue against a 'megadose' effect. The stem cell dose achieved with the currently available technologies is limited. Stem cell doses Ͼ10 ϫ 10 6 CD34 ϩ cells/kg may be achieved in small children, but are difficult to reach in adults. Increasing the stem cell dose by an additional log will require new avenues of stem cell mobilization, harvesting and engineering, such as novel growth factor combinations or ex vivo expansion of peripheral stem cells.
In conclusion, we show that an increased peripheral stem cell dose in the context of haploidentical HSCT using standard myeloablative conditioning is associated with an appreciable rate of graft failure.
